The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 26, 2018

Filed:

Aug. 28, 2014
Applicant:

Vanderbilt University, Nashville, TN (US);

Inventors:

Taekyu Lee, Brentwood, TN (US);

Kwangho Kim, Nashville, TN (US);

Plamen P. Christov, Nashville, TN (US);

Johannes Belmar, Nashville, TN (US);

Jason P. Burke, Houston, TX (US);

Edward T. Olejniczak, Nashville, TN (US);

Stephen W. Fesik, Nashville, TN (US);

Assignee:

Vanderbilt University, Nashville, TN (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 209/26 (2006.01); A61K 31/4045 (2006.01); C07D 401/14 (2006.01); C07D 401/04 (2006.01); C07D 403/04 (2006.01); C07D 413/04 (2006.01); C07D 209/24 (2006.01); A61K 31/404 (2006.01); A61K 31/4155 (2006.01); A61K 31/422 (2006.01); A61K 31/4439 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07D 209/26 (2013.01); A61K 31/404 (2013.01); A61K 31/4045 (2013.01); A61K 31/4155 (2013.01); A61K 31/422 (2013.01); A61K 31/4439 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 209/24 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 413/04 (2013.01);
Abstract

The present application, among other things, provides compounds that are capable of inhibiting the activity of anti-apoptotic Bcl-2 family proteins, for example, myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides pharmaceutical compositions as well as methods for using provided compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein. In some embodiments, a provided compound has the structure of formula I. In some embodiments, a provided compound has the structure of formula II.


Find Patent Forward Citations

Loading…